- Home
- DRTS vs AARD Comparison
DRTS vs AARD Comparison
Compare DRTS & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- AARD
- Stock Information
- Founded
- DRTS 2015
- AARD 2017
- Country
- DRTS Israel
- AARD United States
- Employees
- DRTS N/A
- AARD 31
- Industry
- DRTS Medical/Dental Instruments
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- AARD Health Care
- Exchange
- DRTS Nasdaq
- AARD Nasdaq
- Market Cap
- DRTS 300.2M
- AARD 277.9M
- IPO Year
- DRTS N/A
- AARD 2025
- Fundamental
- Price
- DRTS $3.75
- AARD $12.81
- Analyst Decision
- DRTS Strong Buy
- AARD Strong Buy
- Analyst Count
- DRTS 1
- AARD 7
- Target Price
- DRTS $9.00
- AARD $31.43
- AVG Volume (30 Days)
- DRTS 57.3K
- AARD 154.0K
- Earning Date
- DRTS 11-18-2025
- AARD 11-14-2025
- Dividend Yield
- DRTS N/A
- AARD N/A
- EPS Growth
- DRTS N/A
- AARD N/A
- EPS
- DRTS N/A
- AARD N/A
- Revenue
- DRTS N/A
- AARD N/A
- Revenue This Year
- DRTS N/A
- AARD N/A
- Revenue Next Year
- DRTS N/A
- AARD N/A
- P/E Ratio
- DRTS N/A
- AARD N/A
- Revenue Growth
- DRTS N/A
- AARD N/A
- 52 Week Low
- DRTS $2.14
- AARD $4.88
- 52 Week High
- DRTS $4.69
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- DRTS 44.77
- AARD 46.52
- Support Level
- DRTS $3.75
- AARD $10.75
- Resistance Level
- DRTS $4.25
- AARD $17.94
- Average True Range (ATR)
- DRTS 0.29
- AARD 1.27
- MACD
- DRTS -0.07
- AARD -0.42
- Stochastic Oscillator
- DRTS 1.06
- AARD 12.63
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.